Human cytotoxic T cell responses to vaccinia virus vaccination
S. Graham, l* C. P. Green, 2 P. D. Mason 3 and L. K. Borysiewicz I 1Department of Medicine, Level 5, Addenbrooke's Hospital University of Cambridge, Hills Road, Cambridge CB2 4EB, 2Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH and 3Department of Immunology, Royal Postgraduate Medical School Hammersmith Hospital, Ducane Road, London W12 OHS, U.K. Recombinant vaccinia viruses have been proposed as live virus vectors in man to generate both specific humoral and cellular immune responses. The generation of such responses following revaccination was followed in five normal volunteers. All five showed elevated (35-to 6500-fold) vaccina virusspecific IgG by 14 days post-vaccination, following uncomplicated vaccination by dermal scarification. Four of the five had elevated total serum immunoglobulins with increased spontaneous and pokeweed mitogen-induced immunoglobulin production. Major histocompatibility complex class I-restricted vaccinia virus-specific cytotoxic T lymphocytes (CTLs) were not detected either directly, from peripheral blood mononuclear cells, or following secondary in vitro stimulation, even by limiting dilution analysis. These studies would suggest that vaccination with recombinant vaccinia viruses may provide an insufficient stimulus to the generation of CTLs in vivo.
Recombinant vaccinia viruses have been proposed as a live vector for immunization in man. The use of recombinant vaccines is well established in animals (Smith, 1990) , and protective cellular and humoral immune responses have been observed. The advantages of vaccinia virus include the generation of long-lasting immunity after a single inoculation, established delivery procedures for a population (Fenner et al., 1988) , and a large virus genome (without stringent packaging constraints), permitting multivalent vaccines (Smith, 1990) .
Little is known about specific immune responses in man to this virus. In particular, recombinant vaccinia virus has been proposed to induce cytotoxic T lymphocytes (CTLs) in vivo, and these have been considered the major protective response against poxviruses based upon experimental infection (Fenner et al., 1988) . This may not be the case in man. In a previous study of cellmediated cytotoxic responses to vaccinia virus challenge (Perrin et al., 1977) , major histocompatibility complex (MHC) class 1-restricted cytotoxicity could not be detected.
We have used recombinant vaccinia viruses to investigate the specificity of human CD8 ÷ CTLs in vitro against a number of human viruses including human cytomegalovirus (HCMV); (Borysiewicz et al., 1988b) and human immunodeficiency virus (Gotch et al., 1990) . Members of staff using these recombinant viruses were revaccinated with the vaccine strain of vaccinia virus, which provided an opportunity to re-examine both humoral and specific CTL responses in man.
Five normal healthy laboratory personnel (aged 22 to 35; three female and two male), were revaccinated with 0.02 ml dried smallpox vaccine B.P. (Swiss Serum and Vaccine Institute, Berne, Switzerland; batch 84431). Characteristic local changes were observed in the absence of systemic reactions. Blood samples were taken prior to and 7, 14, 21, 42 and 70 days after revaccination. Control samples were taken from subjects of the same age group who were not revaccinated but had received primary vaccination more than 10 years previously.
Vaccinia virus-specific IgG was estimated by ELISA using vaccinia virus-infected Hep-2 cells or uninfected Hep-2 to coat plates. A titrated vaccinia virus IgG preparation (Public Health Laboratory Service, Colindale, London) was used to calibrate the assay to international units (IU) of vaccinia virus-specific antibody. Specific IgG in serum from vaccinated subjects rose 35-to 6500,fold 14 to 21 days after vaccination compared with prevaccination levels (Table 1) .
Total serum IgG and IgM levels were elevated in four of five subjects (maximal at 7 to 14 days postvaccination), compared with control subjects. In addition IgG and IgM production from isolated peripheral blood mononuclear cells (PBMC) after pokeweed mitogen (Flow Laboratories) stimulation 0001-0036 © 199l SGM was increased, returning to prevaccination levels by 70 days after vaccination, although specific antibody levels remained unchanged (data not shown).
To examine MHC class I-restricted cytotoxicity, PBMCs from vaccinated and control subjects were examined in S lCr release assays either directly or following secondary in vitro stimulation and interleukin 2 (IL-2) culture, to expand numbers of low frequency CTL precursor cells (Borysiewicz et al., 1983; Gotch et al., 1990) . As all subjects were Epstein-Barr virus (EBV)-seropositive and selective vaccination of EBV-seronegative individuals was ethically unacceptable, secondary in vitro stimulation was performed using u.v.-inactivated autologous vaccinia virus strain WR (vac-WR)-infected fibroblasts [m.o.i. = 20:1 for 6 h in the presence or absence of 4 ~tg/ml actinomycin D (Sigma) to inhibit late viral protein expression (Esteban & Metz, 1973) ]. A responder-to-stimulator ratio of 50 : 1 was used, because we have shown previously (Borysiewicz et al., 1988b) that this ratio was able to induce HCMV glycoprotein gB (gB)-specific CTLs using a vaccinia virus recombinant encoding the gB gene from HCMV ADI69 (vac-gB), under identical conditions. More than 95~o of such stimulator cells expressed vaccinia virus proteins as detected by immunofluorescence and fluorescence-activated cell sorter analysis of cells with a potyclonal rabbit anti-vaccinia virus serum (A. Minson, Cambridge). Five IU/ml recombinant IL-2 was added to the co-cultures from initiation, to bypass the requirement for costimulatory activity (Weaver et al., 1988) , and refed every 3 to 4 days. Co-cultured lymphocytes were tested for cytotoxicity after 14 days; the last addition of IL-2 was 4 days prior to assay.
Standard s 1Cr release assays were performed at four effector : target (E : T) ratios using autologous and HLAmismatched fibroblasts, established by explant culture (Borysiewicz et al., 1983) , either infected with vac-WR, infected with vac-WR in the presence of actinomycin D, or uninfected. In addition, K562 target cells with and without 8 ~tg/ml phytohaemagglutinin (Sigma) were studied to determine natural killer (NK) cell activity and total lectin-dependent cytotoxicity (Borysiewicz et al., 1988a) , in both PBMCs and in vitro stimulated cultures. Assays were incubated for 12 h prior to harvest and specific cytotoxicity was estimated as described previously (Borysiewicz et aL, 1983) .
With a single exception (in a pre-vaccination sample from subject LB), HLA-restricted vaccinia virus-specific cytotoxicity was not detected in fresh PBMCs [ Table 2 : studies were performed at multiple E:T ratios but examples at ratios of 100 : 1 (fresh) and 30 : 1 (restimulated) PBMCs are presented]. There was no vaccinia virusspecific cytotoxicity on secondary in vitro stimulation by co-culture. Although a high proportion of the vaccinia virus-specific H2-restricted CTLs in vaccinia virusimmunized mice recognize early or non-structural antigens Mallon et al., 1985) , systematic examination of similarly prepared cells in this study again revealed the absence of HLA-restricted lysis (data not shown).
However, as some cultures exhibited K562 killing or lysis of HLA-mismatched target cells (Table 2) , it remained possible that a low frequency of vaccinia virusspecific MHC class I-restricted CTLs could be present. This may not have been detectable in bulk culture as this killing could be masked by a higher frequency of lymphokine-activated killer or NK cells mediating non-MHC-restricted lysis. To examine whether this was the case we performed limiting dilution analysis to determine the frequency of both specific and non-specific cytotoxicity using partition analysis to separate the two responses (Borysiewicz et al., 1988a; Sharrock et al., 1990) . One of the vaccinees was HCMV-seropositive and PBMCs from this subject were co-cultured in 96-well round-bottomed wells as described (Borysiewicz et al., 1988b) . When individual culture wells were assayed against vac-gB, vac-WR-infected autologous, and HLAmismatched fibroblasts, vac-gB-specific CTLs were present at 1 in 20000 PBMCs, but no vaccinia virusspecific CTLs were detected (i.e. frequency < 1 in l06 in PBMCs).
In revaccinated individuals, there was both specific and non-specific enhancement of antibody production following vaccination, whereas no vaccinia virusspecific MHC class 1-restricted CTLs could be detected in PBMCs, either directly or following secondary in vitro stimulation by co-culture. The failure to generate MHC class I-restricted vaccinia virus-specific CTLs in man may have two broad, not mutually exclusive explanations. The first is inherent in the technique of dermal scarification. Inoculation of animals is often systemic rather than localized by scarification (Koszinowski & Ertl, 1975; Hutt, 1975; Issekutz, 1984) and the dose of virus differs: 10 ~-p.f.u, in man and 107 p.f.u, in mice (Perrin et al., 1977) . There was no systemic reaction in our subjects following vaccination; thus it is possible that an insufficient systemic stimulus was applied. By contrast the stimulus applied was sufficient to induce polyclonal B cell activation with enhanced pokeweed mitogen-induced and spontaneous in vitro antibody production. Furthermore, a systemic reaction is unnecessary to induce secondary virus-specific CTL responses in PBMCs in man, e.g. with killed influenza vaccine administered subcutaneously (McMichael et al., 1981) . As scarification produces a localized infection, PBMCs may be an inappropriate (although the only ethically accessible), lymphocytic compartment to sample. In animal studies, CTL activity is usually detected in lymphocytes from the spleen or draining lymph nodes, and not in PBMCs. Similarly, it is possible that human CTLs could be restricted to such sites.
Secondly, the results of this study are consistent with a specific failure to generate vaccinia virus-specific CTLs in man in vivo. Other vaccinia virus-specific T cell responses are generated, notably proliferative (probably CD4 + T cells) and delayed-type hypersensitivity reactions (Fulginiti et al., 1967; Pincus & Flick, 1963) . In other situations these responses may be the major protective response rather than the CTL one (Nash et al., 1980 (Nash et al., , 1987 .
It is difficult in reporting negative observations to refute totally the suggestion that the failure to observe the response is merely a reflection of the insensitivity of the in vitro detection assays used. It was for this reason that the original observations of Perrin et al. (1977) were reexamined in this study. Within the constraints of ethically justified vaccination we have attempted to use techniques that have been fully validated for other viruses (Borysiewicz et al., 1988a; Hickling et al., 1987; Sharrock et al., 1990) , and by using vac-gB, even controlling the limiting dilution assay internally with a recombinant gene to which PBMCs will respond. It remains possible that vaccinia virus-specific CTLs are present in PBMCs from these subjects, but if so their frequency is less than 1 in 106 PBMC, a value lower than that observed for any other human virus investigated to date.
The negative findings of this study raise doubts as to whether current vaccinia virus-based recombinant vaccines, delivered by dermal scarification, may deliver an adequate stimulus to generate specific CTLs in man. This may represent a clear difference between murine Short communication and human responses, or may be a dose-or routedependent phenomenon. In addition, if recombinant vaccinia virus constructs are used as target or stimulator cells, CTL responses may be observed against the recombinant product without a significant vaccinia virus-specific response.
